Compare Fox Corp Class A (FOXA) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Fox Corporation (FOXA) trades at $55.94, up 1.95% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 14.73 and net income margin of 10.56%, supported by $3.32B in operating cash flow for 2025. Recent news highlights the strategic $22B Roku acquisition, positioning Fox in the competitive streaming landscape.

The outlook is mixed: analyst consensus targets $67.80 (21% upside) with equal buy/hold ratings, but technicals and 2026 cash flow projections signal caution. Key risks include integration challenges from the Roku deal and advertising market volatility. The stock presents a value opportunity if execution risks are managed.

Regeneron (REGN) trades at $656.11, down 1.05% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and has beaten EPS estimates for three consecutive quarters. Recent positive news includes FDA and EMA acceptance of cemdisiran for gMG treatment and selection for an FDA manufacturing review pilot program, reinforcing growth prospects.

Outlook remains positive with a consensus price target of $764.50, implying 16.5% upside. Key opportunities include earnings momentum and regulatory advancements, while risks involve competitive pressures and dependence on key drug performance. Institutional sentiment is strongly bullish with 69% buy ratings, though legal investigations and market volatility warrant monitoring.